A5078717533- Cytomegalovirus and herpesvirus research
- Herpesvirus Infections and Treatments
- Hepatitis B Virus Studies
- Parvovirus B19 Infection Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Toxoplasma gondii Research Studies
- Cervical Cancer and HPV Research
- HIV Research and Treatment
- Viral-associated cancers and disorders
- Viral gastroenteritis research and epidemiology
- Vaccine Coverage and Hesitancy
- Hepatitis Viruses Studies and Epidemiology
- Systemic Lupus Erythematosus Research
- Viral Infections and Immunology Research
- Mycobacterium research and diagnosis
- Animal Virus Infections Studies
- Mosquito-borne diseases and control
- Polyomavirus and related diseases
- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- Cell Image Analysis Techniques
- Neonatal Health and Biochemistry
- T-cell and Retrovirus Studies
- Advanced Fluorescence Microscopy Techniques
Université de Limoges
2016-2025
Inserm
2016-2025
CNR de la Résistance aux Antibiotiques
2014-2024
Hôpital Universitaire Dupuytren
2009-2024
Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques
2014-2024
Centre Hospitalier Universitaire de Limoges
2014-2024
Hôpital Dupuytren
2006-2023
Institut d'Investigació Biomédica de Bellvitge
2021
Bellvitge University Hospital
2021
Université de Bordeaux
2020
Therapies for refractory cytomegalovirus infections (with or without resistance [R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti-cytomegalovirus activity through the inhibition of UL97 protein kinase. In this phase 3, open-label study, hematopoietic-cell and solid-organ with R/R were randomized 2:1 to maribavir 400 mg twice daily investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, cidofovir) 8 weeks, 12 weeks follow-up. The...
Kidney transplant recipients and patients receiving hemodialysis are immunocompromised populations that prioritized for COVID-19 vaccination but were excluded from clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers rates seroconversion after lower among with CKD those taking immunosuppressants compared controls. Data lacking regarding their humoral response to prevent COVID-19.This investigation early serological the Pfizer/BioNTech (BNT162b2) vaccine included 78 undergoing...
Abstract Background This drug resistance analysis of a randomized trial includes 234 patients receiving maribavir and 116 investigator-assigned standard therapy (IAT), where 56% 24%, respectively, cleared cytomegalovirus DNA at week 8 (treatment responders). Methods Baseline posttreatment plasma samples were tested for mutations conferring in viral genes UL97, UL54, UL27. Results At baseline, genotypic testing revealed to ganciclovir, foscarnet, or cidofovir 68% IAT, including 9 newly...
Abstract Cytomegalovirus (CMV) infection and disease are important causes of morbidity mortality in transplant recipients. For the purpose developing consistent reporting CMV outcomes clinical trials, definitions were developed most recently published 2017. Since then, there have been major developments, including registration new antiviral agents. Therefore, Transplant Associated Virus Infections Forum, which consists scientists, clinicians, regulators, industry representatives, has...
Cytomegalovirus (CMV) drug resistance is a therapeutic challenge in the transplant setting. No longitudinal cohort studies of CMV real-life setting have been published valganciclovir era. We report findings for French multicentre prospective 346 patients enrolled at initial diagnosis infection (clinical trial registered clinicaltrials.gov: NCT01008540). Patients were monitored detection ≥2 years. Real-time by UL97 and UL54 gene sequencing antiviral phenotyping was performed if viral...
Variability in the performance of nucleic acid amplification technology (NAT)-based assays presents a significant problem diagnosis and management human cytomegalovirus (HCMV) infections. Here we describe collaborative study to evaluate suitability candidate reference materials harmonize HCMV viral load measurements wide range NAT assays. Candidate comprised lyophilized Merlin virus, liquid AD169 purified DNA cloned into bacterial artificial chromosome. laboratory mean concentrations...
Small intestinal bacterial overgrowth syndrome (SIBOS) is characterized by an abnormally high population level in the upper gut, exceeding 10(5) organisms/ml (5 log colony-forming unit (CFU)/ml). To understand its origin and select appropriate antibiotic treatment, we have analyzed populations contaminating gut SIBOS patients.Jejunal samples of 63 consecutive patients with diarrhea or malabsorption conditions predisposing to were cultured sensitivities determined.Concentrations total,...
Summary. This cross‐sectional study aimed to investigate, during a short period between 2000 and 2001, in large population of patients with chronic hepatitis C, the epidemiological characteristics C virus (HCV) genotypes France. Data from 26 referral centres, corresponding 1769 were collected consecutively 6‐month period. HCV genotyping 5′‐non‐coding region (NCR) was performed each center using line probe assay (LiPA, 63% cases), sequencing (25%) or primer‐specific polymerase chain reaction...
Anti-cytomegalovirus (CMV) prophylaxis is recommended in D+R- kidney transplant recipients (KTR), but associated with a theoretical increased risk of developing anti-CMV drug resistance. This hypothesis was retested this study by comparing 32 KTR who received 3 months (valganciclovir) 80 preemptive treatment. The incidence CMV infections higher the group than prophylactic (60% vs. 34%, respectively; p = 0.02). Treatment failure (i.e. positive DNAemia 8 weeks after initiation treatment) more...
Letermovir potently inhibits the cytomegalovirus (CMV)-terminase complex. primary prophylaxis given for first 3 months after allogeneic hematopoietic cell transplantation (HCT) has been shown to reduce clinically significant CMV infection and is well tolerated. Until now, only case reports or small retrospective series have published on use of letermovir a secondary (SP) diseases HCT. Here we report outcome 80 consecutive CMV-seropositive adult patients included in French compassionate...
ABSTRACT A national evaluation study was performed in 11 specialized laboratories with the objective of assessing their capacities to genotype hepatitis C virus (HCV) and define applicability a given genotyping method. The panel consisted 14 samples positive for HCV RNA different genotypes (including 3 two artificially mixed genotypes) 1 HCV-negative sample. Seventeen sets data were gathered from participating laboratories. sensitivities ranged 64.3 100% 42.7 85.7% methods that used...
The impact of ribavirin exposure on sustained virological response (SVR) in patients with chronic hepatitis C is unknown. Preliminary studies showed marked inter-individual variability concentrations despite dose adjustment for body weight (BW) and suggested there was a correlation between single time point SVR. None them evaluated the global to ribavirin. This study conducted determine whether early related An exploratory pharmacokinetic-pharmacodynamic (PK-PD) genotype 1 treated...
Hepatitis C virus-related B-cell proliferation is a model of virus-driven autoimmune/neoplastic disorder leading to mixed cryoglobulinaemia and/or non-Hodgkin lymphoma. These lymphomas are often marginal zone or diffuse large lymphomas. Peginterferon/Ribavirin therapy has proved its crucial role in the cure these lymphomas, but data lacking concerning new direct anti-viral agents.We report five cases virus-associated lymphoma treated with agents: two received agents alone (one leukaemic...
The first WHO international standard for Epstein-Barr virus (EBV) (WHO EBV standard) nucleic acid amplification technology (NAT)-based assays was commercialized in January 2012 by the National Institute Biological Standards and Control. In study reported here, we compared whole-blood DNA load (EDL) results from 12 French laboratories seven samples (Quality Controls Molecular Diagnostics 2013 proficiency panel) order to determine whether expression units reduces interlaboratory variability...
Antiviral effectors such as natural killer (NK) cells have impaired functions in chronic hepatitis B (CHB) patients. The molecular mechanism responsible for this dysfunction remains poorly characterised. We show that decreased cytokine production capacity of peripheral NK from CHB patients was associated with reduced expression NKp30 and CD16, defective mTOR pathway activity. Transcriptome analysis revealed an enrichment transcripts expressed exhausted T suggesting cell exhaustion employ...
Abstract To identify newborns at risk of developing ASD and to detect biomarkers early after birth, we compared retrospectively ultrasound biological measurements babies diagnosed later with or neurotypical (NT) that are collected routinely during pregnancy birth. We used a supervised machine learning algorithm cross-validation technique classify NT performed various statistical tests. With minimization the false positive rate, 96% 41% were identified predictive value 77%. following related...